Home Featured Page 137

Featured

Latest

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Psychedelic Funding Update: Q1 2026

Inclius Alvarious’s Place Within Indigenous Society

Vice – How to Microdose Drugs Based on What You’re Using

Psychedelic Spotlight – The Top 5 Psychedelics Podcasts

Lucid News – Psychedelic Therapy Training Programs Expand To Meet Demand

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health...

Mindset Pharma to Participate in Upcoming Conferences in December 2022

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Gut Feeling: Links Between LSD, Endocannabinoids, and the Microbiome

PT377 – Integrative Medicine: Health, Wellness, and Psychedelics

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil...

BetterLife Announces Closing of Private Placement

EDITOR PICKS

A Practitioner Statement on the Responsible Development of Ibogaine in the...

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and...

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.